Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 14/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 13/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 12/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 11/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 9/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 8/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9341170 | 0.98 | ADRA2A (0.53) | ADRA2AADRA2CADRA2BADRA1DADRA1A | |
| SCHEMBL8153481 | 0.82 | ADRA2A (0.55) | ADRA2AADRA2CADRA2BADRA1DADRA1A | |
| SCHEMBL7202916 | 0.74 | RIPK2 (0.33) | — | |
| Brimonidine SCHEMBL24670 | 0.71 | ADRA2A (1.00) | ADRA2AADRA2CADRA2BADRA1DADRA1A | |
| SCHEMBL22224522 | 0.71 | ADRA2A (0.59) | ADRA2AADRA2CADRA2BADRA1DADRA1A | |
| Brimonidine SCHEMBL20511531 | 0.71 | ADRA2A (1.00) | ADRA2AADRA2CADRA2BADRA1DADRA1A | |
| Brimonidine SCHEMBL29374525 | 0.71 | ADRA2A (1.00) | ADRA2AADRA2CADRA2BADRA1DADRA1A | |
| Brimonidine SCHEMBL22616115 | 0.70 | ADRA2A (0.97) | ADRA2AADRA2CADRA2BADRA1DADRA1A | |
| Brimonidine SCHEMBL1685506 | 0.70 | ADRA2A (0.97) | ADRA2AADRA2CADRA2BADRA1DADRA1A | |
| SCHEMBL22172211 | 0.69 | ADRA2A (0.51) | ADRA2AADRA2CADRA2BADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0537165-B1 | POLYMERIC DRUG DELIVERY SYSTEM | ALLERGAN INC (US) | 1998-07-01 | — | — | EP | claimed |
| US-5474780-A | Monolithic maleic anhydride drug delivery systems | ALLERGAN, INC. (US) | 1995-12-12 | — | — | US | claimed |
| EP-0630262-A1 | COMPOSITIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICAL COMPOUNDS | ALLERGAN, INC. (US) | 1994-12-28 | — | — | EP | claimed |
| US-5275820-A | Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles | ALLERGAN, INC. (US) | 1994-01-04 | — | — | US | claimed |
| EP-0564537-A1 | STABLE SUSPENSION FORMULATIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICAL COMPOUNDS | ALLERGAN, INC. (US) | 1993-10-13 | — | — | EP | claimed |
| WO-1993017716-A1 | COMPOSITIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICAL COMPOUNDS | ALLERGAN, INC. (US) | 1993-09-16 | — | — | WO | claimed |
| US-5215991-A | Administering amiloride and an imidazolidine derivative | ALLERGAN, INC. (US) | 1993-06-01 | — | — | US | claimed |
| EP-0537165-A1 | POLYMERIC DRUG DELIVERY SYSTEM | ALLERGAN, INC. (US) | 1993-04-21 | — | — | EP | claimed |
| EP-0537165-A4 | POLYMERIC DRUG DELIVERY SYSTEM. | ALLERGAN INC (US) | 1993-02-24 | — | — | EP | claimed |
| US-5180721-A | Imidazoline substituted naphthalene compounds for treatment of glaucoma | ALLERGAN, INC. (US) | 1993-01-19 | — | — | US | claimed |
| WO-1992021349-A1 | COMBINATIONS OF ALPHA-2 ADRENERGIC AGONISTS WITH ALPHA-3 ANTAGONISTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 1992-12-10 | — | — | WO | claimed |
| WO-1992011871-A1 | STABLE SUSPENSION FORMULATIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICAL COMPOUNDS | ALLERGAN, INC. (US) | 1992-07-23 | — | — | WO | claimed |
| WO-1991016869-A1 | POLYMERIC DRUG DELIVERY SYSTEM | ALLERGAN, INC. (US) | 1991-11-14 | — | — | WO | claimed |
| EP-0399791-A1 | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure | ALLERGAN, INC (US) | 1990-11-28 | — | — | EP | claimed |
| CN-114173793-A | Composition, kit and use thereof | 泰瑞威公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-114080220-A | Method for preparing gel-forming composition | 泰瑞威公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-113825498-A | Improved lyophilized formulations comprising hyaluronic acid and plasma proteins and uses thereof | 骨治疗公司 | 2021-12-21 | — | — | CN | disclosed |
| WO-1991016869-A1 | POLYMERIC DRUG DELIVERY SYSTEM | ALLERGAN, INC. (US) | 1991-11-14 | — | — | WO | disclosed |
| US-5021410-A | Administering hypotensive agent to the eye of a mammal | ALLERGAN, INC. (US) | 1991-06-04 | — | — | US | disclosed |
| EP-0399791-A1 | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure | ALLERGAN, INC (US) | 1990-11-28 | — | — | EP | disclosed |